심장 펌프 기기 시장 규모 : 유형별, 기기별, 치료법별, 최종 용도별, 예측(2024-2032년)

Heart pump device market size will register 17.4% CAGR between 2024 and 2032, driven by rising prevalence of cardiovascular diseases worldwide. As per British Heart Foundation, an estimated 200 million people suffer from cardiovascular disorders. Of late, diseases, such as heart failure, coronary artery disease, and cardiomyopathy have become the major reasons for the growing demand for heart pump devices. Moreover, the growing aging population along with the rising unhealthy lifestyles and obesity are increasing the risk of cardiovascular diseases, favoring the product demand.

Minimally invasive procedures associated with heart pumping devices, including shorter recovery times, lower risk of complications, and better patient outcomes are contributing to their increased acceptance among healthcare providers and patients. Strategic initiatives by key market players including product innovations, strategic collaborations, and acquisitions for expanding product portfolios is also stimulating the market growth.

The overall industry is segmented into type, device, therapy, end-use and region.

Based on therapy, the heart pump device market from the bridge to recovery (BTR) therapy segment is anticipated to witness 16% CAGR through 2032, backed by its temporary circulatory support to patients with severe heart failure while awaiting heart transplantation or recovery. This therapy is a lifesaver for patients who are not eligible for an urgent heart transplant and need extra support to help their heart recover from an acute heart attack. Heart pumping devices used in cardiopulmonary resuscitation, such as ventricular assist devices (VADs) also provide mechanical circulatory support to improve heart function and allow patients to stabilize and regain strength while awaiting further treatment.

Heart pump device market from the total artificial hearts (TAH) segment is estimated to generate high revenue at 21.7% CAGR from 2024 to 2032, favored by the rising need for offering a comprehensive solution for patients with end-stage heart failure. Total hearts are designed as a bridge to transplantation or as a permanent solution for patients who are not transplant candidates. Rapid advancements in device technology, including improved biocompatibility, durability, smaller for better patient outcomes and expanding relevant patient populations is favoring the segment growth.

Asia Pacific heart pump device industry size will witness rapid expansion at 18.8% CAGR between 2024-2032. The rapid urbanization and industrialization are contributing to lifestyle-related risk factors, elevating the incidence of CVDs in the region. Advancements in healthcare infrastructure, rising incomes, and healthcare spending in countries, such as China, India, and Japan are driving market growth by improving patient access to advanced cardiac treatments, including heart pump devices.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increase in number of heart failures and cardiovascular diseases
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Rise in awareness regarding heart failure treatment
    • 3.2.1.4 Growing R&D expenditure
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
    • 3.2.2.2 High cost of device and procedures
• 3.3 Growth potential analysis
• 3.4 Porter's analysis
• 3.5 PESTEL analysis
• 3.6 Future market trends
• 3.7 Reimbursement scenario
• 3.8 Regulatory landscape
• 3.9 Technological landscape
• 3.10 GAP analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Implanted heart pump devices
• 5.3 Extracorporeal heart pump devices

Chapter 6 Market Estimates and Forecast, By Device, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Ventricular assist devices (VADs)
  • 6.2.1 Left ventricular assist devices (LVAD)
  • 6.2.2 Right ventricular assist devices (RVAD)
  • 6.2.3 Bi-ventricular assist devices (BiVAD)
  • 6.2.4 Percutaneous ventricular assist devices (PVAD)
• 6.3 Total artificial hearts (TAHs)
• 6.4 Intra-aortic balloon pumps (IABPs)
• 6.5 Extracorporeal membrane oxygenation (ECMO)

Chapter 7 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Destination therapy
• 7.3 Bridge-to-candidacy (BTC) therapy
• 7.4 Bridge-to-transplant (BTT) therapy
• 7.5 Bridge-to-recovery (BTR) therapy
• 7.6 Other therapies

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Cardiac centers
• 8.4 Ambulatory surgical centers
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 ABIOMED
• 10.3 Berlin Heart
• 10.4 BiVACOR Inc.
• 10.5 CARMAT
• 10.6 CorWave SA
• 10.7 Evaheart, Inc.
• 10.8 Fresenius SE & Co. KGaA
• 10.9 Getinge AB
• 10.10 Jarvik Heart
• 10.11 Leviticus Cardio
• 10.12 LivaNova PLC
• 10.13 Medtronic plc
• 10.14 SynCardia Systems, LLC
• 10.15 Teleflex Incorporated